(Bloomberg) -- Bayer AG’s kidney drug Kerendia helped patients avoid complications from a common form of heart failure in a ...

Bayer's two-year-old digital health collaboration ... one-on-one coaching and heart health advice – all delivered and organised via an app. The first iteration of the software is aimed at ...

Merck & Co and Bayer’s heart failure drug vericiguat has hit its target in a phase 3 trial, vindicating a decision by the big US pharma to buy into the project for $1 billion.

Bayer plans to launch Acoramidis, a treatment for a rare heart disease called transthyretin amyloid cardiomyopathy, near the end of the first quarter, as well as elinzanetant, a non-hormonal ...

Bayer acquires rights to Cytokinetics' heart drug in Japan Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development ...

Gadoquatrane, a contrast agent Bayer is developing for use in MRI scans, like those done in MS, uses 60% less gadolinium and ...